152 related articles for article (PubMed ID: 2156889)
1. The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis.
Demers LM; Melby JC; Wilson TE; Lipton A; Harvey HA; Santen RJ
J Clin Endocrinol Metab; 1990 Apr; 70(4):1162-6. PubMed ID: 2156889
[TBL] [Abstract][Full Text] [Related]
2. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
Santen RJ; Demers LM; Lynch J; Harvey H; Lipton A; Mulagha M; Hanagan J; Garber JE; Henderson IC; Navari RM
J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
[TBL] [Abstract][Full Text] [Related]
3. The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro.
Lamberts SW; Bruining HA; Marzouk H; Zuiderwijk J; Uitterlinden P; Blijd JJ; Hackeng WH; De Jong FH
J Clin Endocrinol Metab; 1989 Oct; 69(4):896-901. PubMed ID: 2550511
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of aromatase with CGS 16949A in postmenopausal women.
Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
[TBL] [Abstract][Full Text] [Related]
5. Evidence that corticosterone is not an obligatory intermediate in aldosterone biosynthesis in the rat adrenal.
Häusler A; Monnet G; Borer C; Bhatnagar AS
J Steroid Biochem; 1989; 34(1-6):567-70. PubMed ID: 2533953
[TBL] [Abstract][Full Text] [Related]
6. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A.
Stein RC; Dowsett M; Davenport J; Hedley A; Ford HT; Gazet JC; Coombes RC
Cancer Res; 1990 Mar; 50(5):1381-4. PubMed ID: 2137367
[TBL] [Abstract][Full Text] [Related]
7. Potency and specificity of CGS-16949A as an aromatase inhibitor.
Santen RJ; Langecker P; Santner SJ; Sikka S; Rajfer J; Swerdloff R
Endocr Res; 1990; 16(1):77-91. PubMed ID: 2139412
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of CGS 16949A. A new aromatase inhibitor.
Lipton A; Harvey HA; Demers LM; Hanagan JR; Mulagha MT; Kochak GM; Fitzsimmons S; Sanders SI; Santen RJ
Cancer; 1990 Mar; 65(6):1279-85. PubMed ID: 2137721
[TBL] [Abstract][Full Text] [Related]
9. The effect of the aromatase inhibitor, rogletimide (pyridoglutethimide), on guinea pig adrenal cell steroidogenesis and placental microsomal aromatase activity: comparison with aminoglutethimide and CGS 16949A.
Newton CJ; Mehta A; Dowsett M
J Steroid Biochem Mol Biol; 1991 Nov; 39(5A):723-7. PubMed ID: 1659868
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A.
Steele RE; Mellor LB; Sawyer WK; Wasvary JM; Browne LJ
Steroids; 1987; 50(1-3):147-61. PubMed ID: 2973160
[TBL] [Abstract][Full Text] [Related]
11. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients.
Dowsett M; Stein RC; Mehta A; Coombes RC
Clin Endocrinol (Oxf); 1990 May; 32(5):623-34. PubMed ID: 2142026
[TBL] [Abstract][Full Text] [Related]
12. Novel aromatase inhibitors.
Bhatnagar AS; Häusler A; Schieweck K; Browne LJ; Bowman R; Steele RE
J Steroid Biochem Mol Biol; 1990 Nov; 37(3):363-7. PubMed ID: 2147860
[TBL] [Abstract][Full Text] [Related]
13. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.
Lønning PE; Jacobs S; Jones A; Haynes B; Powles T; Dowsett M
Br J Cancer; 1991 May; 63(5):789-93. PubMed ID: 1828173
[TBL] [Abstract][Full Text] [Related]
14. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor.
Bhatnagar AS; Häusler A; Schieweck K; Lang M; Bowman R
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1021-7. PubMed ID: 2149502
[TBL] [Abstract][Full Text] [Related]
15. CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo.
Schieweck K; Bhatnagar AS; Matter A
Cancer Res; 1988 Feb; 48(4):834-8. PubMed ID: 2962734
[TBL] [Abstract][Full Text] [Related]
16. Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.
Demers LM
Breast Cancer Res Treat; 1994; 30(1):95-102. PubMed ID: 7949208
[TBL] [Abstract][Full Text] [Related]
17. Recent progress in development of aromatase inhibitors.
Santen RJ
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1029-35. PubMed ID: 2149503
[TBL] [Abstract][Full Text] [Related]
18. The constant plasma 18-hydroxycorticosterone to aldosterone ratio: an expression of the efficacy of corticosterone methyloxidase type II activity in disorders with variable aldosterone production.
Kater CE; Biglieri EG; Rost CR; Schambelan M; Hirai J; Chang BC; Brust N
J Clin Endocrinol Metab; 1985 Feb; 60(2):225-8. PubMed ID: 2981240
[TBL] [Abstract][Full Text] [Related]
19. Effect of aromatase inhibitors on estrogen 2-hydroxylase in rat liver.
Purba HS; King EJ; Richert P; Bhatnagar AS
J Steroid Biochem Mol Biol; 1994 Feb; 48(2-3):215-9. PubMed ID: 8142297
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative effect of the new aromatase inhibitor fadrozole on pre- and postmenopausal models of rat mammary tumor.
Tanaka M; Yano S; Hasegawa Y; Nakao K
Arzneimittelforschung; 1994 Jun; 44(6):774-8. PubMed ID: 8053980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
